Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial
T Baptista, N Rangel, Y El Fakih… - …, 2009 - thieme-connect.com
T Baptista, N Rangel, Y El Fakih, E Uzcategui, T Galeazzi, S Beaulieu, EA De Baptista
Pharmacopsychiatry, 2009•thieme-connect.comIntroduction: Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are
important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the
insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in
olanzapine-treated schizophrenia patients. Methods: Thirty patients taking olanzapine (10–
20 mg daily for 8 months) were randomly allocated to rosiglitazone (n= 15; 4 to 8 mg daily)
or placebo (n= 15) in a 12-week double-blind protocol. Anthropometric and biochemical …
important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the
insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in
olanzapine-treated schizophrenia patients. Methods: Thirty patients taking olanzapine (10–
20 mg daily for 8 months) were randomly allocated to rosiglitazone (n= 15; 4 to 8 mg daily)
or placebo (n= 15) in a 12-week double-blind protocol. Anthropometric and biochemical …
Abstract
Introduction: Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients.
Methods: Thirty patients taking olanzapine (10–20 mg daily for 8 months) were randomly allocated to rosiglitazone (n= 15; 4 to 8 mg daily) or placebo (n= 15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12.
Results: The rosiglitazone and placebo groups gained 3.2±4.5 and 2.2±2.3 kg, respectively (p= 0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p< 0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels.
Discussion: The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.
Thieme Connect